Evidence map›Paper›PMID 39668192›Full record

ArticleNature communications2024

Copper chelation redirects neutrophil function to enhance anti-GD2 antibody therapy in neuroblastoma.

Jourdin R C Rouaen, Antonietta Salerno, Tyler Shai-Hee, Jayne E Murray, Giulia Castrogiovanni, Charlotte McHenry, Toni Rose Jue, Vu Pham, Jessica Lilian Bell, Ensieh Poursani and 28 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

38 authors.

Jourdin R C RouaenSchool of Biomedical Sciences, UNSW Medicine & Health, UNSW Sydney, Sydney, NSW, Australia.
Antonietta SalernoSchool of Biomedical Sciences, UNSW Medicine & Health, UNSW Sydney, Sydney, NSW, Australia.ORCID 0009-0003-3927-2302
Tyler Shai-HeeSchool of Biomedical Sciences, UNSW Medicine & Health, UNSW Sydney, Sydney, NSW, Australia.
Jayne E MurraySchool of Biomedical Sciences, UNSW Medicine & Health, UNSW Sydney, Sydney, NSW, Australia.
Giulia CastrogiovanniSchool of Biomedical Sciences, UNSW Medicine & Health, UNSW Sydney, Sydney, NSW, Australia.
Charlotte McHenrySchool of Biomedical Sciences, UNSW Medicine & Health, UNSW Sydney, Sydney, NSW, Australia.
Toni Rose JueChildren's Cancer Institute, Lowy Cancer Research Centre, UNSW Sydney, Sydney, NSW, Australia.ORCID 0000-0002-8449-5973
Vu PhamSchool of Biomedical Sciences, UNSW Medicine & Health, UNSW Sydney, Sydney, NSW, Australia.
Jessica Lilian BellSchool of Biomedical Sciences, UNSW Medicine & Health, UNSW Sydney, Sydney, NSW, Australia.
Ensieh PoursaniSchool of Biomedical Sciences, UNSW Medicine & Health, UNSW Sydney, Sydney, NSW, Australia.
Emanuele ValliDepartment of Experimental Oncology, IEO, European Institute of Oncology IRCCS, Milano, Italy.ORCID 0000-0002-0928-8624
Riccardo CazzoliChildren's Cancer Institute, Lowy Cancer Research Centre, UNSW Sydney, Sydney, NSW, Australia.ORCID 0000-0003-2813-3510
Naomi DamstraInstitute for Respiratory Health, National Centre for Asbestos Related Diseases, University of Western Australia, Perth, WA, Australia.ORCID 0009-0008-1139-2560
Delia J NelsonCurtin Medical School, Curtin Health Innovation Research Institute, Faculty of Health Sciences, Curtin University, Bentley, WA, Australia.
Kofi L P StevensInstitute for Respiratory Health, National Centre for Asbestos Related Diseases, University of Western Australia, Perth, WA, Australia.
Jonathan CheeInstitute for Respiratory Health, National Centre for Asbestos Related Diseases, University of Western Australia, Perth, WA, Australia.ORCID 0000-0002-7986-2708
Iveta SlapetovaKatharina Gaus Light Microscopy Facility, University of New South Wales, Sydney, NSW, Australia.
Maria KashermanKatharina Gaus Light Microscopy Facility, University of New South Wales, Sydney, NSW, Australia.
Renee WhanKatharina Gaus Light Microscopy Facility, University of New South Wales, Sydney, NSW, Australia.
Francis LinSchool of Biotechnology and Biomolecular Sciences, Faculty of Science, UNSW Sydney, Sydney, NSW, Australia.
Blake J CochranSchool of Biomedical Sciences, UNSW Medicine & Health, UNSW Sydney, Sydney, NSW, Australia.
Nicodemus TedlaSchool of Biomedical Sciences, UNSW Medicine & Health, UNSW Sydney, Sydney, NSW, Australia.
Feyza Colakoglu VeliEMBL Australia, Single Molecule Science Node, School of Biomedical Sciences, UNSW Sydney, Sydney, NSW, Australia.
Aysen YukselTumour Bank, Children's Hospital at Westmead, Westmead, NSW, Australia.ORCID 0000-0002-5101-3536
Chelsea MayohSchool of Biomedical Sciences, UNSW Medicine & Health, UNSW Sydney, Sydney, NSW, Australia.ORCID 0000-0002-6398-3046
Federica SalettaChildren's Cancer Institute, Lowy Cancer Research Centre, UNSW Sydney, Sydney, NSW, Australia.
Daniele MercatelliDepartment of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy.ORCID 0000-0003-3228-0580
Tatyana ChtanovaSchool of Biotechnology and Biomolecular Sciences, Faculty of Science, UNSW Sydney, Sydney, NSW, Australia.
Arutha KulasingheFrazer Institute, University of Queensland, Brisbane, QLD, Australia.ORCID 0000-0003-3224-7350
Daniel CatchpooleTumour Bank, Children's Hospital at Westmead, Westmead, NSW, Australia.
Giuseppe CirilloDepartment of Pharmacy Health and Nutritional Science, University of Calabria, Rende, Italy.ORCID 0000-0002-9592-1333
Maté BiroEMBL Australia, Single Molecule Science Node, School of Biomedical Sciences, UNSW Sydney, Sydney, NSW, Australia.
Holger N LodeDepartment of Pediatric Hematology-Oncology, University Medicine Greifswald, Greifswald, Germany.
Fabio LucianiSchool of Biomedical Sciences, UNSW Medicine & Health, UNSW Sydney, Sydney, NSW, Australia.ORCID 0000-0003-0666-6324
Michelle HaberSchool of Biomedical Sciences, UNSW Medicine & Health, UNSW Sydney, Sydney, NSW, Australia.ORCID 0000-0003-2036-8817
Juliet C GrayCentre for Cancer Immunology, University of Southampton, Southampton, UK.
Toby N TrahairSchool of Biomedical Sciences, UNSW Medicine & Health, UNSW Sydney, Sydney, NSW, Australia.ORCID 0000-0002-3295-228X
Orazio VittorioSchool of Biomedical Sciences, UNSW Medicine & Health, UNSW Sydney, Sydney, NSW, Australia. orazio.vittorio@unsw.edu.au.ORCID 0000-0002-6610-1889

Funding

Cancer Council Western Australia CCWA1343Cure Cancer Australia Foundation (CCAF) CCAF2023Department of Health | National Health and Medical Research Council (NHMRC) GNT2012567icare ICARE2023
6 · The paper itself

Abstract

Anti-disialoganglioside (GD2) antibody therapy has provided clinical benefit to patients with neuroblastoma however efficacy is likely impaired by the immunosuppressive tumor microenvironment. We have previously defined a link between intratumoral copper levels and immune evasion. Here, we report that adjuvant copper chelation potentiates anti-GD2 antibody therapy to confer durable tumor control in immunocompetent models of neuroblastoma. Mechanistic studies reveal copper chelation creates an immune-primed tumor microenvironment through enhanced infiltration and activity of Fc-receptor-bearing cells, specifically neutrophils which are emerging as key effectors of antibody therapy. Moreover, we report copper sequestration by neuroblastoma attenuates neutrophil function which can be successfully reversed using copper chelation to increase pro-inflammatory effector functions. Importantly, we repurpose the clinically approved copper chelating agent Cuprior as a non-toxic, efficacious immunomodulatory strategy. Collectively, our findings provide evidence for the clinical testing of Cuprior as an adjuvant to enhance the activity of anti-GD2 antibody therapy and improve outcomes for patients with neuroblastoma.

Indexed as

Chelating AgentsCopperGangliosidesNeuroblastomaNeutrophilsTumor MicroenvironmentAnimalsCell Line, TumorFemaleHumansMiceXenograft Model Antitumor AssaysChelating AgentsCopperganglioside, GD2Gangliosides

Identifiers

PMID39668192
PMCPMC11638255

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.